Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Press/Media
Datasets
Activities
Fellowships, Honors, and Prizes
Search by expertise, name or affiliation
New directions in nicotine vaccine design and use.
Paul R. Pentel, Mark G. LeSage
Medicine - Geriatrics, Palliative and Primary Care (GPPC)
Research output
:
Contribution to journal
›
Article
›
peer-review
71
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New directions in nicotine vaccine design and use.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Immunology and Microbiology
Vaccine Efficacy
100%
Nicotine Vaccine
100%
Hapten
66%
Monospecific Antibody
50%
Antigen
50%
Antibody Blood Level
50%
Gene
16%
Development
16%
Dose
16%
Immunotherapy
16%
Animal
16%
Virus
16%
Immunogenicity
16%
Monoclonal Antibodies
16%
Aptitude
16%
Stoichiometry
16%
Drug Megadose
16%
Conjugate
16%
Position
16%
Density
16%
Conjugate Vaccine
16%
Viral Vector
16%
Adjuvant
16%
Antibody Production
16%
Pharmacology, Toxicology and Pharmaceutical Science
Vaccine
100%
Antibody
100%
Nicotine Vaccine
100%
Hapten
66%
Antigen
50%
Nicotine
33%
Animal
16%
Protein
16%
Immunotherapy
16%
Immunogenicity
16%
Liposome
16%
Virus
16%
Monoclonal Antibody
16%
Adjuvant
16%
Conjugate Vaccine
16%
Peptide
16%
Viral Vector
16%
Biochemistry, Genetics and Molecular Biology
Nicotine
100%
Antibody
50%
Antibody Blood Level
50%
Clinical Trial
33%
Animal
16%
Position
16%
Aptitude
16%
Protein
16%
Development
16%
Nested Gene
16%
Dose
16%
Smoking Cessation
16%
Density
16%
Virus
16%
Peptide
16%
Monoclonal Antibody
16%
Virus Vector
16%
Drug Megadose
16%
Conjugate
16%
Stoichiometry
16%
Antibody Production
16%
Immunogenicity
16%